Press Releases
September 14, 2022
NEW YORK, Sept. 14, 2022 /PRNewswire/ — Neurovation Labs, Inc., a biotechnology company targeting physiological biomarkers of Post-traumatic Stress Disorder (PTSD) for comprehensive diagnosis and treatment, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,439,715, on September 13, 2022. The patent, entitled “Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders,” is directed to novel radiotracer compositions as well as methods for detecting GluA1 and GluA1-containing central nervous system receptors…
June 21, 2022
NEW YORK, Jun. 21, 2022 /PRNewswire/ — Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-traumatic Stress Disorder (PTSD), today announced that it has been awarded a second U.S. Air Force Small Business Innovation Research (SBIR) Direct to Phase II contract through AFWERX and Air Force Research Lab (AFRL). This contract follows a Phase I contract in December 2019 and a Phase II contract in June 2020, where the company gained the sponsorship of the Air Force Special Operations Command (AFSOC) 24th Special Operations Wing to continue development of the PTSD diagnostic and treatment. This Phase II contract will significantly accelerate the development of these pivotal healthcare technologies, as well as explore expansion into detecting Traumatic Brain Injury (TBI), including mild TBI (mTBI)…
January 19, 2022
NEW YORK, Jan. 19, 2022 /PRNewswire/ — Neurovation Labs, Inc., a biotech company targeting physical biomarkers of PTSD for comprehensive diagnosis and treatment, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,224,668, on January 18, 2022. The patent, entitled “Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD,” is directed to novel compositions and methods for diagnosing PTSD as well as treating PTSD following such a diagnosis…
March 8, 2021
NEW YORK, March 8, 2021 /Neurovation Labs/ —Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-traumatic Stress Disorder (PTSD), today announced that it has been selected to advance as Finalists through the highly selective Army Expeditionary Technology Search program (xTechSearch) 5 competition. The xTechSearch competition seeks novel, disruptive concepts and technologies to support the Army’s top modernization priorities that can provide technology advancement or enable cost savings throughout the Army systems’ life cycle. As Finalists, the company received a $120,000 prize as well as an invitation to participate in the Army xTech Accelerator, powered by FedTech, a 6-month long cohort-based program that assists companies in becoming successful dual-use ventures that ultimately transition their technologies into the Army, as well as thrive as small businesses in the United States…
June 25, 2020
NEW YORK, June 25, 2020 /PRNewswire/ — Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-traumatic Stress Disorder (PTSD), today announced that it has been awarded a U.S. Air Force Small Business Innovation Research (SBIR) Phase II contract through AFWERX and Air Force Research Lab (AFRL). This award follows the completion of a successful Phase I contract where the company gained the sponsorship of the Air Force Special Operations Command (AFSOC) 24th Special Operations Wing to pursue the development of the PTSD diagnostic and treatment. Separately, Neurovation Labs was selected to advance through the first stage of the highly selective Army Expeditionary Technology Search program (xTechSearch) v5 competition. The Phase II contract and the xTechSearch award total over $750,000, which will significantly accelerate the development of these pivotal healthcare technologies…
December 16, 2019
NEW YORK, December 16, 2019/ PRNewswire/ — Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-Traumatic Stress Disorder (PTSD), has been awarded a U.S. Air Force Small Business Innovation Research (SBIR) Phase I contract through AFWERX and Air Force Research Lab (AFRL) to advance the development of these pivotal technologies.
Neurovation Labs, Inc. Secures Seed Funding for Post-traumatic Stress Disorder Diagnostic
October 24, 2016
NEW YORK, October 24, 2016/ BusinessWire/ — Neurovation Labs, Inc., a biotechnology company developing Post-traumatic Stress Disorder (“PTSD”) diagnostics and treatments, is pleased to announce that it has successfully raised its seed funding round earlier this month. This financing was completed with the support of individual angel investors based in the United States.